D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136 SEK 1.12% Market Closed
Market Cap: 2.2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Devyser Diagnostics AB
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Capital Expenditures
-kr32m
CAGR 3-Years
-111%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Capital Expenditures
-kr48.6m
CAGR 3-Years
-45%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Capital Expenditures
-kr8.4m
CAGR 3-Years
-66%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Capital Expenditures
-kr156m
CAGR 3-Years
-73%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Capital Expenditures
-kr3.4B
CAGR 3-Years
-9%
CAGR 5-Years
18%
CAGR 10-Years
-42%
BioArctic AB
STO:BIOA B
Capital Expenditures
-kr7.4m
CAGR 3-Years
16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.2B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
123.02 SEK
Overvaluation 10%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Capital Expenditures?
Capital Expenditures
-32m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Capital Expenditures amounts to -32m SEK.

What is Devyser Diagnostics AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-45%

Over the last year, the Capital Expenditures growth was -24%. The average annual Capital Expenditures growth rates for Devyser Diagnostics AB have been -111% over the past three years , -45% over the past five years .

Back to Top